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OBJECTIVE—Insulin contributes to normal brain function. Previous studies have suggested
associations between midlife diabetes and neurodegenerative diseases, including Parkinson’s
disease. Using Danish population registers, we investigated whether a history of diabetes or
the use of antidiabetes drugs was associated with Parkinson’sd i s e a s e .
RESEARCHDESIGNANDMETHODS—FromthenationwideDanishHospitalRegister
hospital records, we identiﬁed 1,931 patients with a ﬁrst-time diagnosis of Parkinson’sd i s e a s e
between 2001 and 2006. We randomly selected 9,651 population control subjects from the
Central Population Registry and density matched them by birth year and sex. Pharmacy records
comprising all antidiabetes and anti-Parkinson drug prescriptions in Denmark were available.
Odds ratios (ORs) were estimated by logistic regression models.
RESULTS—Having diabetes, as deﬁned by one or more hospitalizations and/or outpatient
visits for the condition, was associated with a 36% increased risk of developing Parkinson’s
disease (OR 1.36 [95% CI 1.08–1.71]). Similarly, diabetes deﬁned by the use of any antidiabetes
medications was associated with a 35% increased Parkinson’s disease risk (1.35 [1.10–1.65]).
When diabetes was deﬁned as the use of oral antidiabetes medications, effect estimates were
stronger in women (2.92 [1.34–6.36]), whereas when diabetes was deﬁned as any antidiabetes
drug prescription, patients with early-onset Parkinson’s disease were at highest risk (i.e., Par-
kinson’s disease diagnosed before the age of 60 years; 3.07 [1.65–5.70]).
CONCLUSIONS—We found that a diagnosis of, or treatment received for, diabetes was
signiﬁcantly associated with an increased risk of developing Parkinson’s disease, especially younger-
onsetParkinson’sdisease.Ourresultssuggestacommonpathophysiologic pathwaybetweenthe
two diseases. Future studies should take age at Parkinson’s disease onset into account.
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P
arkinson’s disease is one of the most
commonaging-relatedneurodegen-
erative diseases, characterized by a
progressive loss of dopamine-producing
substantia nigra cells. The loss of dopa-
mine and brain circuitry’s compensatory
actionslead to abroad spectrum ofmotor
and nonmotor features, including muscle
rigidity, slowing of physical movement,
sensory dysfunction, behavioral abnor-
malities, autonomic impairment, and
sleep disturbances (1), all of which
have a dramatic impact on quality of life
in these elderly patients.
Some preliminary evidence emerged
that midlife occurrence of adult-onset
diabetes may result in neurodegenerative
diseases, including Parkinson’sd i s e a s e
(2). Whether this association might in
part be explained by common pathophys-
iologicpathwayscurrentlyisunknown(e.g.,
the GIGYF2 gene involved in both IGF
and insulin-signaling pathways recently
has been identiﬁed as the PARK11 gene,
but current literature does not provide
strong support for its role in Parkinson’s
disease). Nevertheless, it is well known
that insulin plays an important role in
normal brain function, and insulin resis-
tance may lead to neurodegenerative dis-
ease, as suggested by a large study (3) that
reportedahigherincidenceofAlzheimer’s
disease in men who developed diabetes in
midlife, particularly those without the
apolipoprotein E´4a l l e l ek n o w nt oi n -
crease the risk of Alzheimer’s disease.
A number of previous observational
studies (2,4–16) have evaluated the asso-
ciation between diabetes and Parkinson’s
disease and provided mixed results rang-
ing fromprotective to noorpositive asso-
ciations. The aim of this speciﬁc analysis
was to examine whether a history of di-
abetes and, as such, insulin resistance is
linked to Parkinson’s disease. Adding to
previous literature, ours is the ﬁrst and
largest study to examine whether the
type of treatment with antidiabetes drugs
differentiallyaffectstheriskofdeveloping
Parkinson’s disease. Our investigation
was based on a large population-based
case-control study in Denmark, using in-
formationonParkinson’sdiseasefromthe
National Danish Hospital Register and
documenting antidiabetes and anti-
Parkinson’s prescriptions on an individ-
ual level using a nationwide prescription
database.
RESEARCH DESIGN AND
METHODS—Denmark’sN a t i o n a l
Health Service provides free and equal ac-
cess to health care for the entire popula-
tion. Health services–related events are
recorded in national databases, including
theDanishHospitalRegisterandtheDanish
prescription database. Information from
bothregistriescanbelinkedtoeachother
by the use of the unique 10-digit Central
Population Registry number applied to
all residents in Denmark.
We conducted a population-based
case-control study. Parkinson’sd i s e a s e
cases were ascertained from the comput-
erized Danish Hospital Register, with all
hospitalizations with Parkinson’sd i s e a s e
diagnoses registered since 1977 and all
clinic visits, including outpatient clinics,
since1995.Individualinformationonthe
date of death, disappearance, or emigra-
tion was obtained from the Central Pop-
ulation Registry. We identiﬁed 82,140
subjects (13,695 patients with Parkinson’s
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ORIGINAL ARTICLEdisease and 68,445 individuals without
Parkinson’s disease) in the Danish Hospi-
tal Register in the period 1986–2006 who
1) had a valid Central Population Registry
number, 2) were aged .35 years at the
time of diagnosis, and 3)h a dn o te m i -
grated from Denmark. However, to allow
for long enough lag times between diabe-
tes and Parkinson’s disease, only individ-
uals who were registered for the ﬁrst time
with a primary diagnosis of Parkinson’s
disease (ICD-10 code G20) between
January 2001 and December 2006 (or
had no previous hospitalization) were
considered for inclusion as case subjects
in our analyses. To more accurately deﬁne
the “earliest date of a Parkinson’s disease
diagnosis,” we dated the primary Parkin-
son’s disease diagnoses back to either the
ﬁrsthospitaloroutpatientrecordthatever
mentioned Parkinson’s disease or the ﬁrst
prescription of Parkinson’s disease medi-
cations (Anatomical Therapeutic Chemi-
cal [ATC] code N04B) since inception of
the Danish Prescription Database (1995),
whichever came ﬁrst. Patients with Par-
kinson’s disease whose backdated diagno-
sis date fell into the period prior to 2001
were excluded, leaving 2,188 patients
with Parkinson’s disease. Of these, we fur-
ther excluded patients with Parkinson’s
disease who had never received a Parkin-
son’s disease drug prescription (257 case
subjects). To more efﬁciently control for
confounding by the two most important
risk factors for Parkinson’s disease, we
then individually matched ﬁve randomly
selected control subjects (i.e., individuals
without Parkinson’s disease at the index
date)fromtheCentralPopulationRegistry
by sex and year of birth to each case sub-
ject, using incidence-density sampling
(17). The date of Parkinson’s disease diag-
nosis served as the index date for control
selection. This left a total of 1,931 case
subjects with Parkinson’s disease and
9,651 control subjects for our primary
analyses. In secondary analyses, to further
examine the potential for disease misclas-
siﬁcation, we excluded Parkinson’sd i s -
ease case subjects diagnosed with any
type of dementia (both Alzheimer’st y p e
and unspeciﬁed for ICD-8 codes 29009–
29011, 29018–29019, and 29309 and for
ICD-10 codes F00.x, F03, and G30) or
cerebrovascular disease (ICD-8 codes
430–438 and ICD-10 codes I60–I69 and
G45–G46) in the 2 years preceding their
Parkinson’s disease diagnosis (135 case
subjects) and case subjects who used neu-
roleptics (ATC codes N05AA, N05AB,
N05AC, N05AD, N05AF, and N05AG)
inthe6monthsprecedingParkinson’sdis-
easediagnosis(194 casesubjects).Finally,
we obtained a full history of hospitaliza-
tion backdating to 1977 for all case
and control subjects and calculated the
Charlson comorbidity score, a weighted
index of 19 medical conditions (18),
with a lag-time of 5 years prior to index
date as an indicator of baseline morbidity.
The study protocol was approved by the
DanishDataProtectionAgency(no.2002-
41-2112) and the University of California
Los Angeles Human Subject Review
Board.
Assessment of diabetes diagnosis
and antidiabetes drug use
Information on whether Parkinson’sd i s -
ease case and control subjects had a dia-
betesdiagnosispriortotheindexdatewas
extractedbyuseoftheCentralPopulation
Registry number from the National Danish
Hospital Register using the ICD codes for
diabetes (249 and 250.x for ICD-8 and
E10–E14 for ICD-10). Because ICD mis-
classiﬁcation of insulin-dependent diabe-
tes (also known as type 1 diabetes, ICD-8
code249andICD-10codeE10)andnon–
insulin-dependent diabetes (also known
as type 2 diabetes, ICD-8 code 250 and
ICD-10 codes E11–E14) is prevalent
(19,20), and because of inconsistencies
in diabetes codes between ICD-8 and
ICD-10, we chose not to present stratiﬁed
analyses by subtype of diabetes.
Since1January1995,theDanishPre-
scriptionDatabasehasreceiveddataonall
dispensed prescriptions from pharmacies
in Denmark, including the individual’s
Central Population Registry number,
drug type by ATC code, and prescription
dispensingdate.Useofantidiabetesdrugs
by study subjects prior to the index date
wasextractedfromthisdatabase,including
ATC groups A10A (insulins and analogs),
A10B (oral blood glucose–lowering drugs,
including sulfonylureas [e.g., gliclazide]
and biguanides [e.g., metformin]), and
A10x (other drugs used in diabetes). We
deﬁned antidiabetes drug use as any ﬁll-
ing of one or more prescriptions during
the relevant period prior to the index
date; nonusers never ﬁl l e das i n g l ep r e -
scription. We also categorized study par-
ticipants into insulin users versus oral
diabetes medication users according to
ATC code.
Statistical analysis
Weusedunconditionallogisticregression
to calculate odds ratios (ORs) and 95%
CIs for diabetes, while adjusting for age
(continuous), sex, and chronic obstruc-
tive pulmonary disease (COPD; as a
proxy for heavy smoking) diagnosis
(ICD-8 codes 490.00, 491.00, 491.01,
and 491.03 and ICD-10 code J44) identi-
ﬁed in the Danish Hospital Register. Co-
morbidities registered before the index
date (using the Charlson index) were
basedonICDcodes for19chronicdisease
categories recorded in the hospital re-
cords, including diabetes (18). Parameter
estimates changed by ,10% when con-
trolling for the Charlson index in multi-
variate models, so it was excluded from
additional analyses.
To further preclude the possibility of
having included prevalent cases, for our
primary analyses, we advanced (lagged)
the index date for antidiabetes drug pre-
scriptions or diagnosis of diabetes (using
ICD codes) by 2 years (i.e., we excluded
all ﬁrst treatments and diagnoses of di-
abetes within a 2-year period prior to the
index date). In addition, we performed
nonlagged and 5-year-lagged analyses of
Parkinson’s disease. We lagged COPD by
5yearstocapturethegeneralhealthstatus
of subjects prior to the index date. In sec-
ondary analyses, we stratiﬁed by age at
ﬁrst diagnosis (aged #60 and .60 years)
and sex. In sensitivity analyses aimed at
reducing Parkinson’s disease misclassiﬁ-
cation, we excluded case subjects (and
their matched control subjects) and all
controlsubjectsdiagnosed with dementia
orcerebrovasculardisease2yearspriorto
Parkinson’s disease diagnosis of the index
case.
RESULTS—Case subjects and their
control subjects combined were on aver-
age 72.2 years of age (SD 10.2) at the
index date. We identiﬁed more male than
female subjects with a diagnosis of Par-
kinson’s disease. Five years prior to the
index date, case subjects had less COPD
than control subjects, although this dif-
ference was not statistically signiﬁcant
(Table 1). At the index date, 6.4% of our
study population had received a prescrip-
tionforany typeoforal antidiabetesmed-
ication or insulin; antidiabetes drug
prescriptions included oral blood glucose–
lowering drugs, including sulfonylureas
(e.g., gliclazide [43.4%]) and biguanides
(e.g., metformin [25.3%]) as well as in-
sulin (26.6%), and 53% of subjects had
received more than one type of antidia-
betes prescription. The median length of
time for receiving prescriptions for oral
antidiabetes medication since 1995 and
prior to the index date was 5.5 years for
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subjects and for insulin was 6.0 years
among the case subjects versus 4.9 years
in the control subjects.
In our main logistic regression anal-
yses using a 2-year lag and relying on
diabetes diagnoses based on ICD codes,
we estimated an overall 36% increase in
the risk of developing Parkinson’s disease
(95% CI 1.08–1.71) among those with
diabetes (data not shown). In stratiﬁed
analyses (with a 2-year lag), associations
wereslightlystrongerinwomen(OR1.50
[95% CI 1.02–2.22]) than in men (1.29
[0.97–1.72]) and mainly seen in all
patients with early-onset Parkinson’sd i s -
ease (i.e., aged ,60 years at Parkinson’s
disease diagnosis; 2.68 [1.04–6.91])
compared with those with late-onset Par-
kinson’s disease (i.e., aged $60 years
at Parkinson’s disease diagnosis; 1.16
[0.85–1.57]).
Relying on antidiabetes drug use to
identify participants with diabetes, we
found strikingly similar associations,
suggesting a positive association for Par-
kinson’s disease for those who had ever
used antidiabetes drugs .2y e a r sp r i o rt o
Parkinson’s disease onset (OR 1.35 [95%
CI 1.10–1.65]) (Table 2). In analyses
based on 0-year and 5-year lags instead,
our risk estimates were comparable in
size (0-year lag: 1.21 [1.00–1.47]; 5-year
lag: 1.35 [1.07–1.72]). Overall, these as-
sociations were somewhat stronger for
users of oral diabetes medication than
for insulin users (OR 1.37 vs. 1.22) (see
Table 2).
In stratiﬁed analyses (with a 2-year
l a g ) ,r i s ke s t i m a t e sd i f f e r e df o rm e na n d
women and also for those younger (aged
,60 years) or older (aged $60 years)
at diagnosis/index date, whereas the risk
of developing Parkinson’s disease associ-
ated with the use of any type of antidia-
betes drug was very similar for men and
women (men: OR 1.33 [95% CI 1.03–
1.72]; women: 1.38 [0.99–1.92]); among
those using oral diabetes medication,
only women were at higher risk of
developing Parkinson’s disease (men:
0.74 [0.37–1.50]; women: 2.92 [1.34–
6.36]). By contrast, men with diabetes
who use insulin experienced a 48%
higher risk of developing Parkinson’sd i s -
ease (1.48 [1.13–1.95]), whereas the risk
was slightly lower in women (1.20[0.83–
1.74]). Similar to our ICD code–based re-
sults, when stratifying by age at onset of
Parkinson’s disease (aged ,60 years vs.
$60 years at onset), the risk of Parkin-
son’s disease was much higher among pa-
tients with diabetes using antidiabetes
drugs in early onset (3.07 [1.65–5.70])
than in late-onset Parkinson’s disease
(1.24 [0.99–1.53]). On closer examina-
tion, this difference tended to be largely
attributed to insulin use, as opposed to
the use of oral antidiabetes medications:
for early-onset Parkinson’s disease (albeit
based on two cases only), the risk associ-
ated with insulin use was 3.74 (1.89–
7.38) and 1.32 (0.28–6.26) for use of
oral antidiabetes medication, whereas
these risks were 1.24 (0.98–1.57) and
1.21 (0.71–2.06), respectively, for late-
onset Parkinson’s disease. Generally,
theseassociationstendedtobeattenuated
in 0-lag analyses and slightly stronger in
the 5-year lag analyses (data not shown).
When we further stratiﬁed by sex, albeit
based on small case numbers, we found
theseassociationsparticularlyfororalanti-
diabetes medications (we did not have
enough power to examine this for insu-
lin use), again stronger for early-onset
Parkinson’s disease, regardless of sex.
In sensitivity analyses, we excluded
Parkinson’s disease patients and control
subjectsdiagnosedwithdementiaorcere-
brovascular diseases 2 years prior to the
indexdate,buttheriskestimateschanged
only minimally (data not shown). Simi-
larly, excluding case subjects with neuro-
leptic use within 6 months prior to
Parkinson’s disease diagnoses did not al-
ter our ﬁndings substantially (OR for any
use of antidiabetic drugs 1.26 [95% CI
1.01–1.56]).
CONCLUSIONS—We identiﬁed all
case subjects with a primary diagnosis of
Parkinson’sdiseaseinDenmarkfromhos-
pital and outpatient clinic records be-
tween 2001 and 2006. In our analyses,
both ICD code–based hospital and out-
patient clinic reports of diagnoses of di-
abetes (which does not allow us to
distinguish between type 1 and type 2 di-
abetes), as well as the use of antidiabetes
drugs (which, to some degree, allows us
to distinguish between type 1 and type 2
Table 1—Characteristics of the Danish study population, 2001–2006
Parkinson’s disease case subjects Control subjects
n 1,931 9,651
Age (years) 72.2 6 10.5 72.2 6 10.5
Sex
Female 810 (41.9) 4,048 (41.9)
Male 1,121 (58.1) 5,603 (58.1)
Birth year
1900–1909 3 (0.2) 15 (0.2)
1910–1919 254 (13.2) 1,269 (13.2)
1920–1929 737 (38.2) 3,684 (38.2)
1930–1939 568 (29.4) 2,840 (29.4)
1940–1949 266 (13.8) 1,329 (13.8)
1950–1959 73 (3.8) 364 (3.8)
1960–1969 30 (1.5) 150 (1.5)
Age-group (years)
30–40 15 (0.8) 68 (0.7)
41–50 59 (3.1) 298 (3.1)
51–60 183 (9.5) 921 (9.5)
61–70 438 (22.7) 2,190 (22.7)
71–80 753 (39.0) 3,769 (39.1)
81–90 455 (23.6) 2,279 (23.6)
.90 28 (1.5) 126 (1.3)
Charlson index*
0 1,454 (75.3) 7,365 (76.3)
1 251 (13.0) 1,245 (12.9)
$2 226 (11.7) 1,041 (10.8)
COPD*
No 1,910 (98.9) 9,448 (97.9)
Yes 21 (1.1) 203 (2.1)
Data are n (%) or means 6 SD. *Five-year lag: variables are ascertained 5 years prior to the index date or date
of Parkinson’s disease diagnosis; COPD is a proxy for heavy smoking; Charlson comorbidity score is a
weighted index of 19 medical conditions.
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Diabetes and Parkinson’sd i s e a s ediabetes, as individuals using oral diabe-
tes medications only are likely to have
type 2 diabetes), were positively associ-
ated with Parkinson’sdisease.Theseasso-
ciations became stronger with longer lag
times and showed differences in sub-
group analyses (i.e., the associations
were markedly stronger for early-onset
Parkinson’s disease, particularly for insu-
linuse,vs.theriskforearly-onsetdiabetes
and was more modest when oral antidia-
betes drugs were used to treat diabetes).
Among female subjects, oral antidiabetes
drugs were more strongly associated with
overall risk of Parkinson’sd i s e a s et h a n
among men, and oral antidiabetes drugs
also appeared to drive the association
with early-onset diabetes in men.
Observational studies that previously
examined associations between diabetes
and Parkinson’s disease have produced
mixed results. Although most of the pub-
lished epidemiologic studies reported a
positive association between diabetes
and Parkinson’s disease (2,9,10,13) or
Parkinsonian signs (5) and drug-induced
Parkinsonism (4), some studies reported
no association (6,11) and others even in-
verse associations (7,12).
A cross-sectional study of 791 pa-
tients with Parkinsonism that had linked
U.S. National Survey data of 24,831
elderly to 1.9 million Medicare claims
foundthatthosewithParkinsonismhada
50% (men) to 70% (women) higher risk
of concurrent diabetes (13). In a selected
Table 2—Association between diabetes (2-year lag, i.e., diabetes was present at least 2 years prior to the index date) and
Parkinson’s disease*
Case subjects
(n = 1,931)
Control subjects
(n = 9,651)
Adjusted
model 1
Adjusted
model 2
Overall
No diabetes 1,805 9,169 1.0 1.0
Diabetes 126 482 1.33 (1.09–1.63) 1.35 (1.10–1.65)
Men
No diabetes 1,042 5,298 1.0 1.0
Diabetes 79 305 1.32 (1.02–1.70) 1.33 (1.03–1.72)
Women
No diabetes 763 3,871 1.0 1.0
Diabetes 47 177 1.35 (0.97–1.88) 1.38 (0.99–1.92)
Early-onset Parkinson’s disease (aged ,60 years
at Parkinson’s disease diagnosis)
No diabetes 240 1,257 1.0 1.0
Diabetes 17 29 3.09 (1.67–5.73) 3.07 (1.65–5.70)
Late-onset Parkinson’s disease (aged $60 years
at Parkinson’s disease diagnosis)
No diabetes 1,565 7,912 1.0 1.0
Diabetes 109 453 1.22 (0.98–1.51) 1.24 (0.99–1.53)
Analyses by type of antidiabetes drug prescription
Overall
No antidiabetes drug prescription 1,805 9,169 1.0 1.0
Insulin prescription 19 81 1.19 (0.72–1.97) 1.22 (0.74–2.02)
Oral antidiabetes drug prescription 107 401 1.36 (1.09–1.69) 1.37 (1.10–1.71)
Men
No antidiabetes drug prescription 1,042 5,298 1.0 1.0
Insulin prescription 9 63 1.47 (1.12–1.94) 1.48 (1.13–1.95)
Oral antidiabetes drug prescription 70 242 0.73 (0.36–1.47) 0.74 (0.37–1.50)
Women
No antidiabetes drug prescription 763 3,871 1.0 1.0
Insulin prescription 10 18 1.18 (0.82–1.70) 1.20 (0.83–1.74)
Oral antidiabetes drug prescription 37 159 2.82 (1.30–6.13) 2.92 (1.34–6.36)
Early-onset Parkinson’s disease (aged ,60 years
at Parkinson’sd i s e a s ed i a g n o s i s )
No antidiabetes drug prescription 240 1,257 1.0 1.0
Insulin prescription 2 8 3.77 (1.91–7.43) 3.74 (1.89–7.38)
Oral antidiabetes drug prescription 15 21 1.32 (0.28–6.25) 1.32 (0.28–6.26)
Late-onset Parkinson’s disease (aged $60 years
at Parkinson’sd i s e a s ed i a g n o s i s )
No antidiabetes drug prescription 1,565 7,912 1.0 1.0
Insulin prescription 17 73 1.22 (0.97–1.55) 1.24 (0.98–1.57)
Oral antidiabetes drug prescription 92 380 1.18 (0.69–2.00) 1.21 (0.71–2.06)
Data are n or OR (95% CI). Model 1: adjusted for age and sex; model 2: adjusted for age, sex, and COPD (lagged 5 years). *Diagnosis of diabetes based on any
prescription of antidiabetes drugs (ATC codes).
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without a diagnosis of Parkinson’sd i s -
ease, diabetes was found to be associated
with a more severe score of global Parkin-
sonian signs, which was used to deter-
mine the degree of motor dysfunction (5).
Similar to our results, these researchers
also found the association of diabetes
with Parkinsonian signs to be similar
among men and women but stronger in
younger compared with older patients (5).
By contrast, in a case-control study of
490 Parkinson’s disease patients derived
fromaneurologist’sprivate-practicedata-
base, the prevalence of diabetes was
found to be similar in those with and
without Parkinson’s disease (12.9 vs.
12.1%) (11). Three small case-control
studies of 352 (12), 318 (7), and 178
(14) newly diagnosed patients with Par-
kinson’s disease reported inverse associa-
tions with diabetes prior to Parkinson’s
disease (OR 0.52 for men with diabetes
vs. OR 0.80 for women with diabetes in
the ﬁrst, OR 0.40 in the second, and OR
0.30 in the third study). Moreover, a
study based on the U.K. General Practice
Research Database reported the diabetes
prevalence to be similar in patients with
and without Parkinson’sd i s e a s ea n dt h e
risk of developing diabetes to be lower
in Parkinson’s disease patients (6). In
the most recent retrospective study, a
hospital-based case-control study con-
ducted in Japan (16) and comprising
250new-onsetParkinson’sdisease(within
6 years of diagnosis), a decreased risk of
Parkinson’s disease was observed among
individuals with a history of diabetes
(OR 0.38 [95% CI 0.17–0.79]). This
riskdidnotvarybysex; however, neither
was age at onset of Parkinson’sd i s e a s e
nor type of medication used taken into
account in this retrospective analysis.
The few prospective studies that eval-
uated associations between diabetes and
Parkinson’sdiseasepublishedtodatetended
to report positive associations between
the two conditions. In a prospective study
of 51,552 Finnish men and women, a di-
abetes diagnosis at baseline was associated
with an 85% increased risk of developing
Parkinson’sdisease(9).Basedondatafrom
two large prospective cohorts, the Nurses’
HealthStudycohortandtheHealthProfes-
sionals Follow-up Study (15), the relative
risk for developing Parkinson’s diseasewas
1.12 (95% CI 0.69–1.81) among those
with a baseline history of diabetes. The
most detailed study to date was conducted
by Driver et al. (8), who used data from
a large male prospective cohort, the
Physicians’ Health Study. The authors de-
scribe an overall increased risk of Parkin-
son’s disease associated with diabetes
(1.34 [1.01–1.77]), a relative risk strik-
ingly similar in magnitude to our own
ﬁndings. However, in contrast to our
own results, they reported that most of
the excess diabetes risk occurred in the
year prior to and the year of Parkinson’s
disease diagnosis and speculated that this
positive association may therefore either
bedrivenbysurveillancebiasorbyacom-
mon underlying biologic mechanism
causing both diseases and yet to be deter-
mined. In our study, we excluded both
ﬁr s td i a b e t e sd i a g n o s e sb a s e do nI C D
codes as well as antidiabetes drug use by
upto5yearspriortoindexdateandfound
thatassociationstendedtobecomestron-
ger with such lagging, especially when us-
ing antidiabetes medications to identify
diabetic case subjects.
Inapreviouspublicationbasedonthe
same Danish dataset, we explored asso-
ciations between autoimmune diseases,
including insulin-dependent diabetes
deﬁned by ICD-8 code 249 and Parkin-
son’s disease risk during a longer period
of observation (1986–2006) (21). On the
b a s i so fI C Dc o d e sa l o n e ,w eo b s e r v e da
higherriskofParkinson’sdisease(OR1.6
[95% CI 1.02–2.5]) only in women,
whereas no association was apparent
among men using insulin (0.8 [0.5–
1.2])whenlaggingthediabetesdiagnoses
by 5 years. Differences in the present re-
sults are likely attributed to the different
types of diabetes included in the studies
(only insulin-dependent diabetes in the
previous study and both insulin and
non–insulin dependent diabetes in this
study) and possibly also our use of a
more reﬁned Parkinson’s disease deﬁni-
tionbasedonacombinationofParkinson’s
disease ICD codes and Parkinson’s disease
drug prescriptions in the current study.
Insulin has been implicated in Alz-
heimer’s disease risk. Whether this is
primarilya resultof vessel damagecaused
by long-term elevated blood glucose lev-
els as the primary mechanism behind
these associations is currently unknown.
However,giventhatParkinson’sdiseaseis
not primarily a vascular disease, we spec-
ulate that an association between diabetes
and Parkinson’s disease, as found in our
study, could suggest a different pathway,
especially because the associations
seemed to be stronger in younger-onset
Parkinson’s disease (i.e., patients less
likely to be affected by cerebrovascular
disease). One such pathway might be
related to vitamin D levels, which have
been implicated in both diseases (i.e., it
has been suggested that Vitamin D lowers
both the risk of Parkinson’s disease and
type 2 diabetes) (22–24).
We found substantial differences in
estimatedeffectsizebetweendiabetesand
Parkinson’s disease by age at onset of Par-
kinson’s disease, although this difference
is based on small numbers of patients
with early onset. Only one previous
study, examining the association between
diabetes and Parkinsonian signs, was able
to address this, and they too report the
associationbetweendiabeteswithParkin-
sonian signs to be stronger in younger
compared with older patients (5). Al-
though there also were differences for
insulin users versus oral diabetes medica-
tion users in relation to Parkinson’sd i s -
ease by sex and age at onset, statistical
powerissueslimitedourabilitytoexplore
these substrata in greater detail. Overall,
the stronger associations with early-onset
Parkinson’sd i s e a s ea r es u g g e s t i v eo fa
common genetic origin and might serve
as an explanation as to why previous
studies were contradictory, as they were
not able to stratify according to early- or
late-onset Parkinson’s disease.
Recently, an intriguing hypothesis
emerged that may link Parkinson’sd i s -
ease and diabetes via the mitochondrial
dysfunction pathway. Mitochondrialdys-
function has long been suggested as a
pathway in Parkinson’s disease. Neurons
in the substantia nigra (Parkinson’sd i s -
ease) as well as pancreatic islet b-cells (af-
fected in diabetes) have been described as
cells with low respiratory capacity/low
mitochondrial capacity and therefore
have a greater sensitivity to defects or im-
pairments in mitochondrial respiratory
chain enzymes than other cells with
higher respiratory capacity. Thus, both
cell types (substantia nigra and islet
b-cells) are more vulnerable to defects
or toxins that further diminish the capac-
ity to generate ATP when the mitochon-
drial genome accumulates genetic lesions
during aging. In a study comparing 64
Japanese centenarians to 61 patients
with Parkinson’s disease (25), Tanaka
(25) found a by-far-greater frequency of
deleterious mitochondrial variants and a
much greater variety of amino acid re-
placements among Parkinson’s disease
patients; in contrast, such variations
were absent in centenarians. Given the
above-mentioned bioenergetic similarity
of substantia nigra and pancreatic islet
b-cells in terms of their ability to respond
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provide a pathogenetic link between Par-
kinson’s disease and diabetes.
Strengthsofourstudyarethatcontrol
subjects were selected at random from a
population registry and did not have to
volunteer information for our study, thus
avoiding bias attributed to selective non-
participation. We required that all Par-
kinson’s disease case subjects had been
admitted at least once with a primary di-
agnosis of Parkinson’sd i s e a s e ,a n d ,
whenever possible, we dated diagnoses
back to the likely earliest diagnosis
(e.g., a ﬁrst prescription of Parkinson’s
disease medications).
Limitations include some disease
misclassiﬁcation because primary Parkin-
son’s disease diagnoses were identiﬁed
from hospital records that may have in-
cluded some cases of nonidiopathic Par-
kinsonism. Sensitivity analyses in which
weexcludedParkinson’sdiseasecasesub-
jects with prior diagnoses of dementia
and cerebrovascular diseases in the 2
years before Parkinson’s disease diagno-
sis, and Parkinson’s disease case subjects
with neuroleptic use in the 6 months pre-
ceding diagnosis suggested the bias to be
minimal. We might have selected less
healthy Parkinson’s disease case subjects
morelikelytobehospitalizedthanDanish
Parkinson’s disease patients seen exclu-
sively by private practitioners without
ever attending a specialty clinic before
2007. The slightly higher Charlson index
and greater number of cardiovascular dis-
ease drug prescriptions among our
study’sP a r k i n s o n ’s disease patients com-
pared with control subjects 2 years prior
to and at the index date (data not shown)
supports, albeit only modestly, the possi-
bility for such a selection bias. However,
differences in general health status were
not evident 5 years prior to Parkinson’s
disease diagnosis/index date. The uni-
versal coverage of most health care ex-
penses in Denmark, including partial
reimbursement of costs for prescribed
drugs, makes it less likely that antidia-
betes drug prescriptions or Parkinson’s
disease diagnoses were inﬂuenced by
factors determining access to care. In
addition, we may have missed diabetes
case subjects who never took any anti-
diabetes drugs; however, results from
ICD-based diabetes diagnoses were
very similar to those based on antidia-
b e t e sd r u gu s e .W ew e r eu n a b l et of u l l y
control for smoking, known for its
strong negative association with Parkin-
son’s disease, although our adjustment
for COPD as a proxy for heavy smoking
may have, at least partly, controlled for
smoking.
In summary, evidence is accruing for
an association between diabetes and Par-
kinson’sdisease.Whetherthisassociation
is causal or a result of a common patho-
physiologic pathway still needs to be de-
termined, although a common biologic
pathway appears to be the most plausible
explanation at this point. Future studies
of the association between diabetes and
Parkinson’s disease should take age at on-
set of Parkinson’s disease into account.
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